

# Abington

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	15.9	100.9	(57.6-163.8)	Male	13	10.8	120	(63.8-205.2)
Female	5	5.8	86.1	(27.8-201)	Female	12	8.9	135	(69.7-235.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	12	9.5	126.3	(65.2-220.7)
Female	64	65.6	97.5	(75.1-124.5)	Female	8	7.8	102.6	(44.2-202.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.5	nc	(nc-nc)	Male	6	7.4	80.6	(29.4-175.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	19	18.6	102.2	(61.5-159.6)	Female	10	5.9	169.8	(81.3-312.3)
Female	22	18.4	119.2	(74.7-180.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	6	4.5	134.7	(49.2-293.2)	Male	57	63.2	90.1	(68.3-116.8)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	21	9.1	231.7	(143.4-354.2)	Female	18	15	119.8	(71-189.4)
Female	8	5.2	155.3	(66.9-306)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	5	6.4	78.1	(25.2-182.4)
Female	4	0.8	nc	(nc-nc)	Female	8	4.7	169.7	(73.1-334.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	5	5.3	94.6	(30.5-220.8)	Male	45	29.3	153.6	(112-205.6)
Female	1	1.7	nc	(nc-nc)	Female	43	30.4	141.2	(102.2-190.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Acton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	18.4	119.5	(74.8-180.9)	Male	16	13.4	119.7	(68.4-194.4)
Female	8	6.3	126.1	(54.3-248.4)	Female	14	10.8	129.4	(70.7-217.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.3	161.4	(64.7-332.6)	Male	3	3.6	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	5	2.7	187.9	(60.5-438.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	13	11.7	110.9	(59-189.7)
Female	101	82.8	122	(99.4-148.3)	Female	14	9	155.6	(85-261.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.2	nc	(nc-nc)	Male	7	9.6	72.6	(29.1-149.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	22.7	74.8	(43.6-119.8)	Female	13	7.2	181.5	(96.6-310.4)
Female	19	20.8	91.3	(54.9-142.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	6.3	142.7	(65.1-270.9)
Male	4	5.4	nc	(nc-nc)	Female	6	6	99.6	(36.4-216.7)
Female	3	1.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	88	78	112.9	(90.5-139.1)
Male	1	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	0	4.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	2.5	201.1	(64.8-469.2)
Male	12	11.6	103.3	(53.3-180.4)	<b><u>Testis</u></b>				
Female	5	6.1	81.3	(26.2-189.8)	Male	2	2.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	13	16.9	76.7	(40.8-131.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	7.8	77.4	(28.2-168.4)	Female	22	18.6	118.2	(74-179)
Female	9	5.5	164.2	(74.9-311.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	243	272.6	89.1	(78.3-101.1)
Male	1	6.8	nc	(nc-nc)	Female	292	264.4	110.4	(98.1-123.8)
Female	1	2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	16	34.7	46	(26.3-74.8)					
Female	26	34	76.4	(49.9-111.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	12.6	111.1	(60.7-186.4)	Male	9	8.2	109.1	(49.8-207.2)
Female	6	4.3	138	(50.4-300.3)	Female	6	6.2	96.2	(35.1-209.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	2.4	251.5	(91.8-547.4)	Male	3	2.3	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.2	124.7	(56.9-236.8)
Female	45	47.1	95.5	(69.7-127.8)	Female	4	5.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	14.3	118.7	(69.1-190.1)	Female	4	4.2	nc	(nc-nc)
Female	16	13.7	117.1	(66.9-190.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	4.2	120.2	(38.7-280.6)
Male	4	3.4	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	64	48.4	132.2	(101.8-168.9)
Male	4	1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	2	3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.7	nc	(nc-nc)
Male	9	6.8	132.1	(60.3-250.7)	<b><u>Testis</u></b>				
Female	5	3.8	133.1	(42.9-310.7)	Male	0	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	1.9	nc	(nc-nc)	Male	2	3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	12	8.7	138.7	(71.6-242.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	4.8	nc	(nc-nc)	Female	9	10.9	82.9	(37.8-157.4)
Female	4	3.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	198	170.9	115.8	(100.3-133.1)
Male	3	4	nc	(nc-nc)	Female	158	160.2	98.6	(83.9-115.3)
Female	0	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	26	23.2	112.1	(73.2-164.2)					
Female	19	22.8	83.2	(50.1-129.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Adams

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	12.2	82.2	(39.4-151.2)	Male	9	7.4	121.5	(55.4-230.6)
Female	3	4.6	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	6.5	152.9	(73.2-281.3)
Female	33	42.9	76.8	(52.9-107.9)	Female	7	5.7	122.4	(49-252.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	1	4.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	13.1	129.3	(75.3-207.1)	Female	4	4	nc	(nc-nc)
Female	14	14.4	97.1	(53-162.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	3.9	127.6	(41.1-297.8)
Male	3	3.1	nc	(nc-nc)	Female	7	4.5	155	(62.1-319.3)
Female	1	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	55	42.2	130.3	(98.1-169.6)
Male	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.8	nc	(nc-nc)
Male	5	5.9	84.9	(27.4-198.1)	<b><u>Testis</u></b>				
Female	3	3.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	7.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	4.4	nc	(nc-nc)	Female	9	9.9	91.3	(41.7-173.4)
Female	1	3.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	159	154.2	103.1	(87.7-120.4)
Male	2	3.5	nc	(nc-nc)	Female	143	154.5	92.6	(78-109.1)
Female	0	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	22	21.8	100.9	(63.2-152.8)					
Female	33	23.2	142.5	(98-200.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Agawam

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	36.1	83.1	(56.1-118.7)	Male	22	22.7	96.7	(60.6-146.4)
Female	17	14.6	116.7	(67.9-186.9)	Female	13	18.8	69.2	(36.8-118.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.5	139.3	(63.5-264.4)	Male	3	6.4	nc	(nc-nc)
Female	4	5.7	nc	(nc-nc)	Female	1	5.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	23	20.1	114.3	(72.4-171.5)
Female	156	139.3	112	(95.1-131)	Female	17	18.2	93.4	(54.4-149.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.7	149.2	(59.8-307.5)	Male	19	14.9	127.2	(76.5-198.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	40	40.5	98.7	(70.5-134.4)	Female	12	12.9	92.7	(47.8-161.9)
Female	48	46.2	103.9	(76.6-137.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	11.8	76.5	(34.9-145.2)
Male	9	9.4	95.4	(43.5-181.1)	Female	11	14.2	77.3	(38.5-138.3)
Female	2	2.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	110	128.9	85.3	(70.1-102.8)
Male	0	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	7	2.2	325.1	(130.2-669.8)	Male	15	8.5	177	(99-292)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	5.8	86.6	(27.9-202.1)
Male	20	18.4	108.9	(66.5-168.2)	<b><u>Testis</u></b>				
Female	9	11.4	79	(36-149.9)	Male	3	4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	5.1	nc	(nc-nc)	Male	6	7.9	76.2	(27.8-165.8)
Female	0	1.7	nc	(nc-nc)	Female	16	23.8	67.1	(38.3-109)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	13.6	44	(16.1-95.8)	Female	23	31.7	72.6	(46-108.9)
Female	7	10.9	64	(25.7-132)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	442	470.5	93.9	(85.4-103.1)
Male	5	10.9	45.9	(14.8-107.1)	Female	481	494.5	97.3	(88.8-106.4)
Female	3	4.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	74	64.4	114.9	(90.2-144.2)					
Female	77	71.1	108.3	(85.4-135.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Alford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0	nc	(nc-nc)	Male	0	0	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Male</u></b>				
Male	0	0.1	nc	(nc-nc)	Obs	5	12.1	41.4	(13.3-96.6)
Female	0	0	nc	(nc-nc)	<b><u>Female</u></b>				
<b><u>Leukemia</u></b>					Obs				
Male	0	0.3	nc	(nc-nc)	7	9	77.6	(31.1-159.9)	
Female	0	0.2	nc	(nc-nc)					
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	0	1.7	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Amesbury

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	15.7	146.1	(92.6-219.2)	Male	14	10.8	129.5	(70.8-217.3)
Female	8	6.2	129.8	(55.9-255.8)	Female	12	9.3	129.3	(66.7-225.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	5	2.9	170.4	(54.9-397.6)
Female	5	2.8	175.9	(56.7-410.6)	Female	3	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	9.5	115.8	(57.7-207.2)
Female	79	68.5	115.3	(91.3-143.7)	Female	13	8.2	158.5	(84.3-271)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	13	7.4	175.5	(93.3-300.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	21	18.5	113.4	(70.1-173.3)	Female	8	6.2	130	(56-256.1)
Female	29	19.8	146.2	(97.9-209.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	5.3	133.1	(53.3-274.3)
Male	10	4.4	227	(108.7-417.5)	Female	6	6	100.8	(36.8-219.4)
Female	1	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	59	61.9	95.3	(72.5-122.9)
Male	2	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	0	3.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	2.4	nc	(nc-nc)
Male	2	9.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	5.4	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	8	13.4	59.6	(25.6-117.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	6.4	141.1	(64.4-267.9)	Female	15	15.5	97	(54.3-160)
Female	5	5	100	(32.2-233.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	236	220.9	106.8	(93.6-121.4)
Male	4	5.3	nc	(nc-nc)	Female	268	231.7	115.7	(102.2-130.4)
Female	4	1.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	36	29	124.1	(86.9-171.8)					
Female	39	31.5	123.9	(88.1-169.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Amherst

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	19.2	72.8	(39.8-122.1)	Male	9	13.4	67.2	(30.7-127.6)
Female	4	7.6	nc	(nc-nc)	Female	12	13.3	90.1	(46.5-157.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	4.8	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	4	4.3	nc	(nc-nc)	Female	0	3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	12.5	80.3	(38.4-147.7)
Female	80	79.4	100.8	(79.9-125.4)	Female	13	10.5	123.6	(65.7-211.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.1	nc	(nc-nc)	Male	7	8.6	81.7	(32.8-168.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	21.8	55	(28.4-96.1)	Female	11	7.9	138.9	(69.2-248.5)
Female	15	24.3	61.6	(34.5-101.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	63	71.9	87.6	(67.3-112.1)
Female	0	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	3.7	nc	(nc-nc)	Male	2	6.5	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	10.4	96.3	(46.1-177.1)	Female	13	18.4	70.8	(37.6-121)
Female	6	6.5	92.1	(33.6-200.5)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	8	8.9	89.9	(38.7-177.1)
Female	1	0.9	nc	(nc-nc)	Female	5	7	71.5	(23-166.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	3	6.1	nc	(nc-nc)	Male	13	34.8	37.4	(19.9-63.9)
Female	1	2.3	nc	(nc-nc)	Female	19	38.2	49.7	(29.9-77.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Andover

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	34	73.6	(47.6-108.7)	Male	19	23	82.5	(49.6-128.8)
Female	9	12.8	70.5	(32.2-133.9)	Female	20	18.8	106.3	(64.9-164.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	7.1	nc	(nc-nc)	Male	6	6.4	94.4	(34.5-205.4)
Female	4	5.8	nc	(nc-nc)	Female	6	5.2	115.7	(42.2-251.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	24	20.2	118.6	(76-176.5)
Female	133	143.1	93	(77.8-110.2)	Female	19	16.9	112.3	(67.6-175.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	5.1	nc	(nc-nc)	Male	20	16.1	124	(75.7-191.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	31	40	77.6	(52.7-110.1)	Female	21	12.8	164.3	(101.6-251.1)
Female	35	41.1	85.1	(59.3-118.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	11.4	78.9	(36-149.8)
Male	7	9.6	72.9	(29.2-150.2)	Female	13	12.3	105.7	(56.2-180.8)
Female	4	2.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	137	136.1	100.6	(84.5-119)
Male	2	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	10	8.3	120.8	(57.8-222.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	5	nc	(nc-nc)
Male	13	19.5	66.5	(35.4-113.8)	<b><u>Testis</u></b>				
Female	6	11.1	53.9	(19.7-117.4)	Male	5	4.2	117.8	(38-274.9)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	5.3	nc	(nc-nc)	Male	13	8.7	148.6	(79.1-254.2)
Female	1	1.6	nc	(nc-nc)	Female	32	26.7	119.8	(81.9-169.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	19	13.5	140.2	(84.4-219)	Female	34	32.3	105.1	(72.8-146.9)
Female	9	10.2	87.9	(40.1-166.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	416	477.2	87.2	(79-96)
Male	11	11.6	95.1	(47.4-170.2)	Female	440	479.2	91.8	(83.4-100.8)
Female	1	3.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	29	63.1	46	(30.8-66)					
Female	45	65.4	68.8	(50.2-92.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	0	0.6	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Arlington

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	49.1	79.5	(56.5-108.7)	Male	34	31.5	107.9	(74.7-150.8)
Female	21	20.2	103.7	(64.2-158.6)	Female	35	27.7	126.4	(88-175.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	9.1	66	(24.1-143.6)	Male	11	8.7	126	(62.8-225.4)
Female	8	8.4	95.3	(41.1-187.9)	Female	9	8.1	111.6	(50.9-211.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	21	27.7	75.8	(46.9-115.9)
Female	230	203.9	112.8	(98.7-128.4)	Female	28	25.9	108.2	(71.9-156.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	7.3	nc	(nc-nc)	Male	16	20.3	78.7	(45-127.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	43	54.9	78.3	(56.7-105.5)	Female	18	18.6	96.6	(57.2-152.6)
Female	57	64	89.1	(67.5-115.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	15	12.8	116.8	(65.3-192.7)	Male	147	175.5	83.8	(70.8-98.5)
Female	4	4.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	8	6.2	128.4	(55.3-253)
Female	3	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	24	25.4	94.3	(60.4-140.3)	Female	42	46.2	91	(65.6-123)
Female	16	16.6	96.4	(55.1-156.6)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	3	7	nc	(nc-nc)	Male	15	18.7	80.3	(44.9-132.5)
Female	2	2.4	nc	(nc-nc)	Female	17	15.5	109.6	(63.8-175.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	16	14.8	108.3	(61.9-175.9)	Male	76	88.4	86	(67.7-107.6)
Female	3	5.8	nc	(nc-nc)	Female	82	102.5	80	(63.6-99.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashburnham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	5.4	167.9	(76.6-318.8)	Male	1	3.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	1	1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	22	21.8	100.9	(63.2-152.7)	Female	4	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	6.6	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	7	5.3	130.9	(52.5-269.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	1.8	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	26	23.1	112.3	(73.4-164.6)
Male	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.6	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.3	nc	(nc-nc)	Female	7	4.9	142.8	(57.2-294.3)
Female	1	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	73	80.1	91.2	(71.5-114.6)
Male	0	2	nc	(nc-nc)	Female	71	69.4	102.3	(79.9-129.1)
Female	0	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	10.2	59	(21.5-128.4)					
Female	7	8.8	79.1	(31.7-163)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	2.8	215	(78.5-468)	Male	3	2	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	12	11.5	104.4	(53.9-182.3)	Female	4	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	3.4	nc	(nc-nc)	Female	4	1	nc	(nc-nc)
Female	2	3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	10	12.1	82.6	(39.5-151.8)
Male	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.2	nc	(nc-nc)	Female	5	2.6	193.6	(62.4-451.7)
Female	2	0.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	37	41.7	88.7	(62.5-122.3)
Male	0	1	nc	(nc-nc)	Female	44	37.1	118.5	(86.1-159.1)
Female	2	0.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	5.3	112.5	(41.1-244.8)					
Female	2	4.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	14	8.7	161.2	(88.1-270.5)	Female	1	1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	2.7	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	10	9.2	108.2	(51.8-199)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	25	31.9	78.4	(50.7-115.7)
Male	0	0.8	nc	(nc-nc)	Female	30	28.1	106.7	(72-152.3)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	0	4.2	nc	(nc-nc)					
Female	1	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashland

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	14.4	104.4	(58.4-172.1)	Male	7	10.3	68.3	(27.3-140.6)
Female	4	5	nc	(nc-nc)	Female	3	8.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.3	nc	(nc-nc)	Male	7	2.7	254.7	(102-524.8)
Female	1	2.6	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	7	9	78.2	(31.3-161.1)
Female	66	63.4	104.1	(80.5-132.4)	Female	6	7	85.2	(31.1-185.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.5	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	17.3	52	(23.7-98.7)	Female	12	5.5	216.7	(111.8-378.5)
Female	20	16.1	124.6	(76.1-192.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	4.9	123.2	(45-268.1)
Male	7	4.1	168.8	(67.6-347.7)	Female	3	4.7	nc	(nc-nc)
Female	2	1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	47	59	79.6	(58.5-105.9)
Male	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	1.9	nc	(nc-nc)
Male	12	8.8	137	(70.7-239.4)	<b><u>Testis</u></b>				
Female	3	4.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	6	4.2	144.2	(52.7-313.9)
Female	0	0.7	nc	(nc-nc)	Female	19	13.3	143.2	(86.2-223.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	5.9	nc	(nc-nc)	Female	14	14.5	96.7	(52.8-162.3)
Female	7	4.3	164.1	(65.7-338)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	176	208.4	84.5	(72.5-97.9)
Male	4	5.1	nc	(nc-nc)	Female	219	205.5	106.5	(92.9-121.6)
Female	3	1.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	23	27	85.3	(54.1-128)					
Female	36	27.1	132.7	(92.9-183.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Athol

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	14	114.2	(65.2-185.4)	Male	7	8.8	79.3	(31.8-163.3)
Female	6	5.3	114	(41.6-248.1)	Female	5	7	71.8	(23.1-167.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.6	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.8	76.5	(27.9-166.5)
Female	31	51.1	60.7	(41.2-86.2)	Female	5	6.6	75.3	(24.3-175.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.8	nc	(nc-nc)	Male	10	5.7	174.5	(83.6-321)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	15.7	95.8	(53.6-158)	Female	5	4.7	105.7	(34.1-246.7)
Female	11	16.7	65.8	(32.8-117.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	7	3.6	192.5	(77.1-396.6)	Male	35	49.5	70.6	(49.2-98.2)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	4	1.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	7.1	112.6	(48.5-222)	Female	21	11.5	182.3	(112.8-278.6)
Female	4	4.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	2	2	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	4	148.5	(54.2-323.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	5	4.2	119.8	(38.6-279.5)	Male	37	25	148.1	(104.3-204.2)
Female	1	1.5	nc	(nc-nc)	Female	25	25.9	96.4	(62.3-142.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Attleboro

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	41.8	114.8	(84.6-152.2)	Male	27	28.4	95	(62.6-138.2)
Female	11	16.2	67.8	(33.8-121.3)	Female	18	24	75.1	(44.5-118.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	8.8	136.2	(70.3-238)	Male	4	7.7	nc	(nc-nc)
Female	8	7.4	107.7	(46.4-212.1)	Female	5	6.5	76.7	(24.7-179)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	16	25	64	(36.5-103.9)
Female	166	173.4	95.7	(81.7-111.5)	Female	16	21.4	74.7	(42.7-121.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.6	91.3	(33.3-198.7)	Male	24	19	126.4	(80.9-188)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	56	48.5	115.5	(87.2-150)	Female	25	15.7	158.8	(102.8-234.5)
Female	43	51.9	82.9	(60-111.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	15	13.9	108.2	(60.5-178.5)
Male	9	11.4	78.7	(35.9-149.4)	Female	15	15.7	95.4	(53.4-157.4)
Female	3	3.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	151	159.2	94.9	(80.3-111.2)
Male	7	3.9	177.6	(71.2-365.9)	<b><u>Stomach</u></b>				
Female	2	3.2	nc	(nc-nc)	Male	8	10.1	79.2	(34.1-156.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	8	6.4	125.5	(54-247.3)
Male	21	23.5	89.5	(55.4-136.9)	<b><u>Testis</u></b>				
Female	15	13.8	108.6	(60.7-179.1)	Male	7	6.8	103.1	(41.3-212.5)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	6.3	79.4	(25.6-185.2)	Male	10	11	91.2	(43.6-167.7)
Female	3	2	nc	(nc-nc)	Female	27	34.4	78.5	(51.7-114.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	16.9	53.4	(24.4-101.4)	Female	33	39.1	84.5	(58.1-118.6)
Female	10	13.1	76.1	(36.4-139.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	585	577.2	101.4	(93.3-109.9)
Male	15	13.5	110.7	(61.9-182.6)	Female	557	597.4	93.2	(85.7-101.3)
Female	11	4.8	231	(115.2-413.4)					
<b><u>Lung and Bronchus</u></b>									
Male	105	76.4	137.4	(112.3-166.3)					
Female	86	82.5	104.2	(83.4-128.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Auburn

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	22.4	89.2	(54.5-137.8)	Male	9	13.8	65.1	(29.7-123.5)
Female	11	8	137.7	(68.6-246.3)	Female	7	10.6	66.2	(26.5-136.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	5	3.2	154.4	(49.8-360.4)	Female	5	3.2	157.1	(50.6-366.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	9	12.2	73.6	(33.6-139.8)
Female	73	79.2	92.2	(72.3-115.9)	Female	11	10.1	108.7	(54.2-194.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.7	nc	(nc-nc)	Male	16	8.9	180.1	(102.9-292.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	23	24.6	93.4	(59.2-140.2)	Female	8	7.3	109.9	(47.3-216.6)
Female	25	25.1	99.5	(64.4-146.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	7.3	110.3	(47.5-217.3)
Male	4	5.8	nc	(nc-nc)	Female	9	7.8	115.9	(52.9-220.1)
Female	1	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	60	78.5	76.4	(58.3-98.3)
Male	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	7	5.2	134.9	(54.1-278)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	3.1	nc	(nc-nc)
Male	14	11.1	126.5	(69.1-212.2)	<b><u>Testis</u></b>				
Female	5	6.5	77.3	(24.9-180.3)	Male	4	2.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	3.1	160	(51.5-373.3)	Male	3	4.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	18	13.7	131.2	(77.7-207.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	8.3	108.5	(49.5-205.9)	Female	22	18.1	121.4	(76-183.7)
Female	5	6	83	(26.8-193.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	257	287	89.5	(78.9-101.2)
Male	4	6.5	nc	(nc-nc)	Female	275	277.7	99	(87.7-111.4)
Female	0	2.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	39	40	97.4	(69.2-133.1)					
Female	42	40.4	103.9	(74.9-140.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Avon

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	5.6	125.8	(50.4-259.2)	Male	3	3.5	nc	(nc-nc)
Female	1	2	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1	nc	(nc-nc)	Male	1	1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	26	21.1	123.1	(80.4-180.4)	Female	3	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	6.2	80.7	(26-188.3)	Female	3	1.9	nc	(nc-nc)
Female	4	6.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	1.8	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	2	2	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	8	20.5	39	(16.8-76.9)
Male	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.8	nc	(nc-nc)
Male	6	2.9	208.4	(76.1-453.7)	<b><u>Testis</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	2.1	239	(77-557.8)	Female	2	4.9	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	76	73.4	103.5	(81.6-129.6)
Male	4	1.7	nc	(nc-nc)	Female	74	72.9	101.6	(79.7-127.5)
Female	0	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	15	10.1	148	(82.8-244.2)					
Female	15	10.8	138.4	(77.4-228.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ayer

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.5	77.3	(24.9-180.4)	Male	4	4.5	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	6	3.9	155.4	(56.7-338.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	4	1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	4	nc	(nc-nc)
Female	30	27.8	107.9	(72.8-154.1)	Female	3	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	2	3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	7.6	65.5	(21.1-152.9)	Female	4	2.5	nc	(nc-nc)
Female	9	8.3	108.8	(49.6-206.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	2.2	nc	(nc-nc)
Male	5	1.8	278.4	(89.7-649.7)	Female	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	21	25.1	83.5	(51.7-127.7)
Male	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.7	nc	(nc-nc)	Female	10	6.2	161.1	(77.1-296.4)
Female	0	2.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	84	91.3	92	(73.4-113.9)
Male	2	2.2	nc	(nc-nc)	Female	102	95.7	106.6	(86.9-129.5)
Female	1	0.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	12	159	(95.7-248.2)					
Female	13	13.2	98.6	(52.4-168.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Barnstable

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	89	73.2	121.6	(97.6-149.6)	Male	58	43.8	132.4	(100.5-171.2)
Female	26	24.7	105.2	(68.7-154.2)	Female	50	31.6	158.1	(117.4-208.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	11.7	102.2	(52.7-178.5)	Male	9	12.6	71.4	(32.6-135.6)
Female	12	9.7	123.2	(63.6-215.3)	Female	15	9.9	152.1	(85.1-250.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	43	38.7	111.2	(80.5-149.8)
Female	286	240.2	119.1	(105.7-133.7)	Female	39	31	125.9	(89.5-172.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	7.8	128.2	(61.4-235.8)	Male	25	27.4	91.3	(59.1-134.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	63	78.5	80.3	(61.7-102.7)	Female	19	22.1	85.9	(51.7-134.2)
Female	79	76	103.9	(82.3-129.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	22	23.5	93.8	(58.8-142)
Male	15	18.5	81.3	(45.5-134.1)	Female	29	23.9	121.3	(81.2-174.2)
Female	3	5.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	315	249.6	126.2	(112.6-140.9)
Male	3	4.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	3.6	nc	(nc-nc)	Male	19	16.6	114.1	(68.7-178.3)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	9.4	nc	(nc-nc)
Male	31	34.6	89.7	(60.9-127.3)	<b><u>Testis</u></b>				
Female	18	19.9	90.3	(53.5-142.7)	Male	9	6.3	143.2	(65.3-271.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	10	10	100.4	(48.1-184.7)	Male	11	13.8	79.6	(39.7-142.5)
Female	3	3	nc	(nc-nc)	Female	26	39.7	65.4	(42.7-95.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	38	26.3	144.5	(102.2-198.4)	Female	58	55.9	103.8	(78.8-134.2)
Female	30	18.1	165.5	(111.6-236.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	977	914.6	106.8	(100.2-113.7)
Male	19	20.5	92.6	(55.7-144.6)	Female	936	846.9	110.5	(103.5-117.8)
Female	9	7.1	127.4	(58.1-241.8)					
<b><u>Lung and Bronchus</u></b>									
Male	98	130.6	75	(60.9-91.4)					
Female	133	127.6	104.2	(87.3-123.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Barre

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	5.7	123.8	(49.6-255.1)	Male	2	3.8	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	0	1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	15	21	71.4	(39.9-117.8)	Female	1	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	6.6	136.7	(62.4-259.4)	Female	1	1.9	nc	(nc-nc)
Female	6	6.1	97.9	(35.7-213.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	26	21.8	119.5	(78-175.1)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	3.2	190.2	(69.4-413.9)	Female	8	4.7	170.7	(73.5-336.4)
Female	1	1.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	8	10.4	77.2	(33.3-152.2)
Female	0	0.6	nc	(nc-nc)	Female	8	9.7	82.4	(35.5-162.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Becket

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	11	8.1	136.6	(68.1-244.4)	Female	2	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.8	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Female	8	10.3	77.7	(33.5-153.1)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.9	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	0.8	nc	(nc-nc)	Female	7	1.9	363.8	(145.8-749.7)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	4	4.7	nc	(nc-nc)	Female	23	34.6	66.4	(42.1-99.7)
Female	2	3.7	nc	(nc-nc)	Female	30	26.5	113.4	(76.5-161.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bedford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	21.2	84.8	(50.2-134)	Male	13	12.6	103.1	(54.8-176.3)
Female	4	5.9	nc	(nc-nc)	Female	3	7.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	10	11.2	89.1	(42.7-163.9)
Female	58	60.3	96.3	(73.1-124.4)	Female	9	7.6	119.1	(54.4-226.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	8	7.9	100.9	(43.4-198.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	23	104.4	(66.9-155.3)	Female	1	5.5	nc	(nc-nc)
Female	22	18.7	117.6	(73.7-178.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	6.8	132.4	(60.4-251.3)
Male	4	5.3	nc	(nc-nc)	Female	6	5.8	104.2	(38-226.8)
Female	3	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	71	70.4	100.8	(78.8-127.2)
Male	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	2.3	nc	(nc-nc)
Male	8	10	80.4	(34.6-158.4)	<b><u>Testis</u></b>				
Female	4	4.9	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	4	4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	10	10.4	96.1	(46-176.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	7.7	116.8	(53.3-221.7)	Female	15	13.8	109	(61-179.8)
Female	5	4.5	110.5	(35.6-257.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	236	262.6	89.9	(78.8-102.1)
Male	5	5.9	84.7	(27.3-197.7)	Female	194	208.8	92.9	(80.3-107)
Female	0	1.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	24	37.3	64.3	(41.2-95.7)					
Female	31	30	103.3	(70.1-146.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Belchertown

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	12.4	56.7	(22.7-116.7)	Male	10	8.9	112.9	(54.1-207.7)
Female	4	4.3	nc	(nc-nc)	Female	7	7.4	94.7	(38-195.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	2.8	246.5	(98.8-507.9)	Male	2	2.4	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	14	7.8	180.1	(98.4-302.2)
Female	44	55	80	(58.1-107.4)	Female	4	6.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	15.1	73.1	(36.4-130.7)	Female	4	4.8	nc	(nc-nc)
Female	11	13.9	78.9	(39.3-141.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	4.2	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	Female	5	4.1	122.6	(39.5-286.1)
Female	1	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	57	51	111.7	(84.6-144.8)
Male	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1	nc	(nc-nc)	Male	5	3.1	161.9	(52.2-377.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.7	nc	(nc-nc)
Male	6	7.6	79.3	(29-172.7)	<b><u>Testis</u></b>				
Female	2	4.1	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	7	11.6	60.3	(24.2-124.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	5.2	nc	(nc-nc)	Female	13	12.5	103.9	(55.3-177.7)
Female	1	3.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	169	180.2	93.8	(80.2-109)
Male	5	4.4	112.5	(36.2-262.5)	Female	145	177.9	81.5	(68.8-95.9)
Female	1	1.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	17	23	73.8	(42.9-118.1)					
Female	19	23.1	82.2	(49.5-128.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bellingham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	14.4	62.5	(28.5-118.7)	Male	4	10.3	nc	(nc-nc)
Female	7	5.1	138.2	(55.4-284.7)	Female	8	8.4	95.5	(41.1-188.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.3	184.1	(67.2-400.7)	Male	1	2.8	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	13	9	145.1	(77.2-248.1)
Female	75	62.6	119.8	(94.2-150.2)	Female	12	7.1	169.7	(87.6-296.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.4	nc	(nc-nc)	Male	8	7.2	111.1	(47.9-219)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	16	17.2	92.8	(53-150.7)	Female	2	5.5	nc	(nc-nc)
Female	12	16.1	74.4	(38.4-129.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	6	4.2	143.3	(52.3-311.9)	Male	70	60	116.7	(91-147.5)
Female	1	1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	8.8	113.9	(54.5-209.5)	Female	18	14.3	125.6	(74.4-198.5)
Female	3	4.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	5	5.9	84	(27.1-196.1)
Female	0	0.7	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	6	5.1	117.9	(43.1-256.7)	Male	35	27.1	128.9	(89.8-179.3)
Female	0	1.6	nc	(nc-nc)	Female	29	27.7	104.9	(70.2-150.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Belmont

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	30	93.5	(62.1-135.1)	Male	19	18.8	101.1	(60.9-158)
Female	7	11	63.6	(25.5-131)	Female	12	15.2	79.1	(40.8-138.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	5.4	130.2	(52.2-268.3)	Male	5	5.3	94.6	(30.5-220.9)
Female	6	4.7	128.5	(46.9-279.7)	Female	3	4.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	17	16.6	102.5	(59.7-164.1)
Female	122	113.5	107.5	(89.3-128.4)	Female	11	14.2	77.6	(38.7-138.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	4	nc	(nc-nc)	Male	6	12.1	49.4	(18-107.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	22	33.3	66	(41.4-100)	Female	12	10.3	116.3	(60-203.2)
Female	29	34.9	83	(55.6-119.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	9.8	71.8	(28.8-147.9)
Male	5	7.8	64.3	(20.7-150)	Female	8	10.7	74.9	(32.3-147.6)
Female	2	2.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	101	106.4	94.9	(77.3-115.3)
Male	3	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	5	7	71.5	(23-166.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	4.3	nc	(nc-nc)
Male	11	15.2	72.6	(36.2-129.9)	<b><u>Testis</u></b>				
Female	3	9.1	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	4.2	nc	(nc-nc)	Male	8	6.4	124.2	(53.5-244.7)
Female	1	1.3	nc	(nc-nc)	Female	24	20.6	116.7	(74.8-173.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	11.3	nc	(nc-nc)	Female	22	25.7	85.5	(53.6-129.5)
Female	5	8.5	58.8	(18.9-137.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	314	388.6	80.8	(72.1-90.3)
Male	3	8.9	nc	(nc-nc)	Female	345	392.6	87.9	(78.8-97.6)
Female	4	3.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	37	53.7	68.9	(48.5-94.9)					
Female	35	55.8	62.7	(43.7-87.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Berkley

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.6	nc	(nc-nc)	Male	5	3.6	139.6	(45-325.7)
Female	1	1.5	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.1	191.6	(70-417.1)
Female	29	21.2	136.9	(91.7-196.7)	Female	3	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	5.9	102.1	(37.3-222.2)	Female	0	1.8	nc	(nc-nc)
Female	5	5	100.6	(32.4-234.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	1.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	18	20.7	87.1	(51.6-137.7)
Male	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.6	nc	(nc-nc)
Male	5	3.2	158.6	(51.1-370)	<b><u>Testis</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	0	1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	5	4.9	101.8	(32.8-237.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2	nc	(nc-nc)	Female	6	4.7	128.5	(46.9-279.8)
Female	3	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	71	71.9	98.7	(77.1-124.5)
Male	0	1.8	nc	(nc-nc)	Female	79	66.8	118.3	(93.6-147.4)
Female	0	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	8.9	67.5	(24.6-146.9)					
Female	7	8.2	85.8	(34.4-176.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Berlin

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	1	2	nc	(nc-nc)
Female	10	12.8	78	(37.4-143.5)	Female	1	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	3.9	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	1.1	441.1	(142.2-1029.4)
Male	1	1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	11	13.8	79.9	(39.8-143)
Male	2	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	5	1.9	262	(84.4-611.5)	Male	0	0.4	nc	(nc-nc)
Female	0	1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Leukemia</u></b>					Female	4	2.9	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	53	47.3	112	(83.9-146.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female	37	42.6	86.8	(61.1-119.6)
Male	0	1.1	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	9	6.3	142	(64.8-269.5)					
Female	6	6.1	99	(36.1-215.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bernardston

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	3.2	157.2	(50.6-366.8)	Male	2	2	nc	(nc-nc)
Female	1	1	nc	(nc-nc)	Female	5	1.4	359.7	(115.9-839.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	6	10.7	56.1	(20.5-122.2)	Female	3	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	3.6	nc	(nc-nc)	Female	3	1	nc	(nc-nc)
Female	5	3.1	160.4	(51.7-374.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	19	12	158.4	(95.3-247.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.6	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	1	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Beverly

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	50	44.8	111.6	(82.9-147.2)	Male	30	28.8	104.2	(70.3-148.8)
Female	23	17.5	131.1	(83.1-196.7)	Female	32	24	133.1	(91-187.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	8.4	118.6	(56.8-218.1)	Male	8	8	100	(43.1-197.1)
Female	9	7.4	121.9	(55.6-231.5)	Female	4	7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	31	25.4	121.8	(82.8-173)
Female	166	175.1	94.8	(80.9-110.4)	Female	23	22.4	102.7	(65.1-154.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	6.2	nc	(nc-nc)	Male	22	18.9	116.2	(72.8-175.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	31	50.5	61.4	(41.7-87.1)	Female	17	16.2	105.2	(61.2-168.4)
Female	53	55.8	95	(71.2-124.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	14.7	81.8	(42.2-142.9)
Male	20	11.9	168.6	(102.9-260.3)	Female	15	17.1	87.8	(49.1-144.9)
Female	2	3.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	190	163.3	116.4	(100.4-134.1)
Male	4	3.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	3.1	nc	(nc-nc)	Male	7	10.6	66.3	(26.6-136.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	6.9	72.3	(23.3-168.7)
Male	28	23.4	119.9	(79.6-173.2)	<b><u>Testis</u></b>				
Female	18	14.2	126.7	(75-200.2)	Male	9	5.7	156.9	(71.6-298)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	6.5	77.3	(24.9-180.3)	Male	12	10.3	116.7	(60.2-203.9)
Female	3	2.1	nc	(nc-nc)	Female	35	32.2	108.7	(75.7-151.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	16	17.3	92.7	(52.9-150.5)	Female	33	39.6	83.3	(57.3-116.9)
Female	9	13.6	66.1	(30.2-125.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	632	593.7	106.5	(98.3-115.1)
Male	16	13.8	116.1	(66.3-188.5)	Female	629	615.6	102.2	(94.3-110.5)
Female	10	5	198.6	(95.1-365.2)					
<b><u>Lung and Bronchus</u></b>									
Male	74	80.8	91.6	(71.9-115)					
Female	92	87.4	105.3	(84.9-129.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Billerica

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	50	35.2	142	(105.3-187.1)	Male	36	25.7	139.9	(98-193.7)
Female	17	12.3	138.7	(80.7-222.1)	Female	22	20.3	108.2	(67.8-163.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	8.2	85	(34-175.1)	Male	9	6.8	131.4	(60-249.5)
Female	6	6.3	95.4	(34.8-207.6)	Female	6	5.1	117.2	(42.8-255.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	20	22.3	89.5	(54.7-138.3)
Female	136	151.7	89.7	(75.2-106)	Female	18	17.2	104.9	(62.1-165.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	5.9	85.2	(27.4-198.7)	Male	16	18.3	87.5	(50-142.1)
<b><u>Colon / Rectum</u></b>					Female	4	7.1	nc	(nc-nc)
Male	40	42.8	93.6	(66.8-127.4)	<b><u>Ovary</u></b>				
Female	39	39.1	99.8	(71-136.5)	Female	14	13.4	104.4	(57-175.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	10.5	85.6	(39.1-162.5)	Male	14	12.1	116.1	(63.4-194.7)
Female	3	2.5	nc	(nc-nc)	Female	12	11.6	103.1	(53.2-180)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	144	152.9	94.2	(79.4-110.9)
Female	0	2.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	8.9	124.2	(61.9-222.3)
Male	27	22.1	122	(80.4-177.5)	Female	4	4.7	nc	(nc-nc)
Female	11	11.6	94.5	(47.1-169.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	6.4	125.1	(53.9-246.4)
Male	5	5.9	84.9	(27.4-198.2)	<b><u>Thyroid</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	15	10.7	140.7	(78.7-232.1)
<b><u>Leukemia</u></b>					Female	29	31.1	93.1	(62.3-133.7)
Male	20	14.8	135.6	(82.8-209.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	10.3	203	(125.6-310.4)	Female	27	35.2	76.7	(50.5-111.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	12.8	77.8	(37.3-143.2)	Male	576	525.8	109.5	(100.8-118.9)
Female	3	3.8	nc	(nc-nc)	Female	503	496.6	101.3	(92.6-110.5)
<b><u>Lung and Bronchus</u></b>									
Male	81	67.2	120.6	(95.7-149.8)					
Female	93	66.5	139.8	(112.8-171.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Blackstone

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.9	114.1	(52.1-216.7)	Male	5	5.6	89.9	(29-209.9)
Female	5	2.9	172.6	(55.6-402.7)	Female	4	4.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	1.8	281.1	(90.6-656)	Male	0	1.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.9	101.9	(32.8-237.8)
Female	30	34.1	88	(59.3-125.6)	Female	4	4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	9.5	94.8	(43.3-180)	Female	3	3	nc	(nc-nc)
Female	5	9.3	53.6	(17.3-125)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	6	2.2	268.7	(98.1-584.9)	Male	33	31.4	105.3	(72.4-147.8)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	3	0.8	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	4.7	nc	(nc-nc)	Female	9	7.7	117	(53.4-222.1)
Female	4	2.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	25	14.5	171.9	(111.2-253.8)
Female	0	0.9	nc	(nc-nc)	Female	18	15.3	117.6	(69.7-185.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Blandford

### Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	1	1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	1.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	6.4	108.7	(43.5-223.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	0.9	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.5	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	3	2.8	nc	(nc-nc)	Male	17	21.7	78.3	(45.6-125.4)
Female	2	2.2	nc	(nc-nc)	Female	16	16.8	95.1	(54.3-154.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bolton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	3.8	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	20	17.6	113.8	(69.5-175.7)	Female	1	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	4.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	1	4	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	1	0.4	nc	(nc-nc)	Female	27	18.1	149.6	(98.5-217.6)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	1	2.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	1	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	3	1.6	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	1	1.6	nc	(nc-nc)	Female	12	4	302.6	(156.2-528.6)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	5	7.3	68.2	(22-159.1)	Female	65	60	108.3	(83.6-138.1)
Female	5	6.6	75.8	(24.4-177)	Female	51	54.2	94.1	(70.1-123.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boston

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	347	452.1	76.8	(68.9-85.3)	Male	262	314.3	83.4	(73.6-94.1)
Female	131	179.7	72.9	(60.9-86.5)	Female	216	291.9	74	(64.5-84.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	81	102.2	79.3	(63-98.5)	Male	105	82.3	127.6	(104.4-154.5)
Female	78	90.4	86.3	(68.2-107.7)	Female	106	72.3	146.6	(120-177.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	9	14.2	63.2	(28.8-120)	Male	284	278.4	102	(90.5-114.6)
Female	1830	1943.4	94.2	(89.9-98.6)	Female	231	243.6	94.8	(83-107.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	92	80	115	(92.7-141)	Male	246	203.3	121	(106.4-137.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	614	522.5	117.5	(108.4-127.2)	Female	180	180.1	99.9	(85.9-115.6)
Female	623	571.9	108.9	(100.5-117.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	116	122.4	94.8	(78.3-113.7)	Male	141	149.4	94.4	(79.4-111.3)
Female	43	36.4	118.1	(85.5-159.1)	Female	190	173.6	109.4	(94.4-126.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	48	56.1	85.5	(63.1-113.4)	Male	144	109.1	132	(111.3-155.4)
Female	57	49.5	115.2	(87.2-149.3)	Female	109	70.1	155.6	(127.7-187.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	253	253	100	(88-113.1)	Male	89	105.1	84.7	(68-104.2)
Female	192	156.6	122.6	(105.9-141.2)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	88	67.1	131.1	(105.1-161.5)	Female	444	440.6	100.8	(91.6-110.6)
Female	25	22.8	109.8	(71-162.1)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	144	190.1	75.7	(63.9-89.2)	Male	6778	6298.2	107.6	(105.1-110.2)
Female	117	153.1	76.4	(63.2-91.6)	Female	6736	6811.2	98.9	(96.5-101.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	265	144	184	(162.5-207.5)					
Female	89	53.3	167.1	(134.2-205.6)					
<b><u>Lung and Bronchus</u></b>									
Male	904	822.1	110	(102.9-117.4)					
Female	847	927.7	91.3	(85.3-97.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bourne

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	26.6	131.5	(91.6-182.9)	Male	19	16.5	115.4	(69.5-180.3)
Female	11	9.4	116.7	(58.2-208.8)	Female	13	12.2	106.4	(56.6-181.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.6	130.1	(47.5-283.3)	Male	7	4.7	150.3	(60.2-309.6)
Female	6	3.8	158.7	(57.9-345.4)	Female	5	3.8	133	(42.9-310.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.5	110.3	(63-179.1)
Female	99	91.5	108.2	(87.9-131.7)	Female	9	11.9	75.9	(34.6-144.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3	nc	(nc-nc)	Male	11	10.5	105.2	(52.5-188.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	27	28.8	93.6	(61.7-136.2)	Female	18	8.5	212.3	(125.7-335.5)
Female	22	29.1	75.5	(47.3-114.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	8.6	69.6	(25.4-151.6)
Male	7	6.9	101.4	(40.6-209)	Female	9	9.1	98.5	(44.9-187)
Female	6	1.9	311.5	(113.7-678)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	115	94.9	121.2	(100-145.4)
Male	0	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	6	6.1	98	(35.8-213.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	3.6	nc	(nc-nc)
Male	11	13.1	83.7	(41.7-149.8)	<b><u>Testis</u></b>				
Female	4	7.6	nc	(nc-nc)	Male	1	3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	3.7	160	(58.4-348.3)	Male	0	5.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	17	15.5	109.9	(64-176)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	9.9	101.3	(48.5-186.3)	Female	22	21.4	103	(64.5-155.9)
Female	6	7	85.4	(31.2-185.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	379	343.2	110.4	(99.6-122.1)
Male	5	7.8	64.4	(20.8-150.3)	Female	345	323.9	106.5	(95.6-118.4)
Female	0	2.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	57	48.2	118.1	(89.5-153.1)					
Female	59	48.4	121.9	(92.8-157.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	8	2.9	272.2	(117.2-536.3)
Female	1	1.1	nc	(nc-nc)	Female	6	2.3	261.8	(95.6-569.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	23	17.6	130.4	(82.6-195.7)	Female	5	1.7	286.8	(92.4-669.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	4.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	7	3.8	182.4	(73.1-375.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	1.2	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	1	0.4	nc	(nc-nc)	Female	26	17	153	(99.9-224.1)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	1	2.6	nc	(nc-nc)	Female	0	1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	1	0.7	nc	(nc-nc)	Female	4	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	3	1.7	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	1.5	nc	(nc-nc)	Female	6	4	151.9	(55.5-330.6)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	3	7.1	nc	(nc-nc)	Female	62	59.1	104.8	(80.4-134.4)
Female	5	6.4	78.4	(25.3-183)	Female	71	53.6	132.6	(103.5-167.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boxford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	8.6	93.3	(40.2-183.8)	Male	18	5.9	303.5	(179.8-479.7)
Female	0	2.6	nc	(nc-nc)	Female	7	4.2	165.5	(66.3-340.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
Female	46	33.4	137.6	(100.7-183.5)	Female	1	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	10.3	77.9	(33.6-153.6)	Female	2	2.9	nc	(nc-nc)
Female	5	8.3	60.5	(19.5-141.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	47	36.3	129.5	(95.2-172.2)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	1	1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	5.1	nc	(nc-nc)	Female	4	7.6	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	8	3.4	233.1	(100.4-459.4)
Female	1	0.4	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	7	16.2	43.1	(17.3-88.9)
Female	0	0.8	nc	(nc-nc)	Female	5	13.9	36	(11.6-84)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	4.7	107	(34.5-249.7)	Male	2	3.2	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	25	18.8	132.7	(85.9-195.9)	Female	0	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	5.5	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
Female	8	5	161.3	(69.4-317.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	18	19.4	92.6	(54.9-146.4)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	2.8	nc	(nc-nc)	Female	1	4.3	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	4	8.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	7	8.4	83.1	(33.3-171.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	52	43.9	118.4	(88.4-155.3)	Male	32	27.4	116.8	(79.9-165)
Female	20	17.1	117.2	(71.5-181)	Female	28	22.4	124.9	(83-180.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	7.8	102.5	(44.1-202)	Male	9	7.7	116.5	(53.1-221.1)
Female	7	6.9	100.8	(40.4-207.7)	Female	7	6.8	103.2	(41.3-212.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	23	24.2	95.2	(60.3-142.8)
Female	172	167.3	102.8	(88-119.4)	Female	17	21.5	78.9	(46-126.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	5.7	140.6	(60.5-277)	Male	19	17.6	107.9	(65-168.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	50	48.3	103.5	(76.8-136.4)	Female	19	15.4	123.5	(74.3-192.9)
Female	78	53.3	146.3	(115.7-182.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	13	14.2	91.3	(48.5-156.1)
Male	14	11.4	122.9	(67.1-206.2)	Female	18	16.6	108.5	(64.3-171.5)
Female	5	3.5	144.3	(46.5-336.8)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	147	155.9	94.3	(79.7-110.9)
Male	4	3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	5	2.6	190.7	(61.5-445.1)	Male	11	10.2	108	(53.8-193.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	10	6.6	151.4	(72.5-278.4)
Male	23	22	104.4	(66.2-156.6)	<b><u>Testis</u></b>				
Female	14	13.8	101.7	(55.6-170.7)	Male	4	4.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	6.2	nc	(nc-nc)	Male	7	9.3	75.4	(30.2-155.3)
Female	3	2	nc	(nc-nc)	Female	40	29	137.7	(98.4-187.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	16.5	72.9	(37.6-127.3)	Female	39	38.2	102	(72.5-139.5)
Female	12	12.9	93	(48-162.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	582	567.7	102.5	(94.4-111.2)
Male	19	13	146.6	(88.2-229)	Female	665	589.6	112.8	(104.4-121.7)
Female	5	4.9	102.8	(33.1-239.8)					
<b><u>Lung and Bronchus</u></b>									
Male	77	79.1	97.4	(76.9-121.7)					
Female	99	86.4	114.5	(93.1-139.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	20.6	72.8	(40.7-120.1)	Male	16	11.5	138.9	(79.4-225.6)
Female	8	7.2	111.7	(48.1-220.2)	Female	17	8.1	209	(121.7-334.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.3	116.9	(60.3-204.2)
Female	76	62.3	122	(96.1-152.7)	Female	10	8.6	116.7	(55.9-214.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	8	6.9	115.6	(49.8-227.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	18	21.4	84	(49.7-132.7)	Female	2	5.9	nc	(nc-nc)
Female	16	22.1	72.4	(41.3-117.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	4.9	nc	(nc-nc)	Male	5	6.5	77	(24.8-179.8)
Female	3	1.4	nc	(nc-nc)	Female	5	7	71.3	(23-166.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	7	8.8	79.5	(31.9-163.8)	Male	0	1.1	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.6	nc	(nc-nc)	Female	18	14.5	124.4	(73.7-196.7)
Female	0	0.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	7.1	112.9	(48.6-222.4)	Male	227	243.2	93.3	(81.6-106.3)
Female	2	5	nc	(nc-nc)	Female	203	227.7	89.2	(77.3-102.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	2	5.3	nc	(nc-nc)					
Female	0	2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	28	35.8	78.2	(52-113.1)					
Female	17	35	48.6	(28.3-77.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	21.6	125	(82.3-181.8)	Male	17	15.9	106.6	(62.1-170.7)
Female	11	7.1	155.2	(77.4-277.8)	Female	15	11.7	128.3	(71.8-211.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.2	115.6	(42.2-251.6)	Male	2	4.2	nc	(nc-nc)
Female	5	3.7	136	(43.8-317.4)	Female	5	2.9	171.4	(55.2-400)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	7	14	50	(20-103.1)
Female	84	83.8	100.3	(80-124.1)	Female	10	9.8	101.9	(48.8-187.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.2	nc	(nc-nc)	Male	8	11.2	71.6	(30.8-141.2)
<b><u>Colon / Rectum</u></b>					Female	9	4	225.3	(102.8-427.7)
Male	22	26.4	83.3	(52.2-126.2)	<b><u>Ovary</u></b>				
Female	29	22.7	127.9	(85.6-183.7)	Female	11	7.5	145.9	(72.7-261.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.3	126.6	(54.5-249.5)	Male	9	7.4	121.8	(55.6-231.3)
Female	2	1.4	nc	(nc-nc)	Female	6	6.8	88.6	(32.4-192.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	90	90.4	99.5	(80-122.3)
Female	1	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	5.4	nc	(nc-nc)
Male	13	13.5	96	(51.1-164.3)	Female	5	2.7	182.6	(58.8-426.1)
Female	4	6.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	4.7	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1	nc	(nc-nc)	Male	10	6.8	147	(70.4-270.4)
<b><u>Leukemia</u></b>					Female	20	17.7	112.8	(68.9-174.2)
Male	7	9.2	75.8	(30.4-156.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	6.1	nc	(nc-nc)	Female	14	19.1	73.4	(40.1-123.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	7.8	128.9	(61.7-237.1)	Male	326	321.1	101.5	(90.8-113.2)
Female	3	2.2	nc	(nc-nc)	Female	293	280.6	104.4	(92.8-117.1)
<b><u>Lung and Bronchus</u></b>									
Male	58	40.7	142.6	(108.3-184.4)					
Female	33	37.7	87.4	(60.2-122.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brimfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	15	15.4	97.6	(54.6-161.1)	Female	2	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	4.7	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	14	16.5	84.7	(46.3-142.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	0.5	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	2.3	255.5	(93.3-556.1)	Female	4	3.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.6	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	50	57	87.7	(65.1-115.6)
Female	1	1	nc	(nc-nc)	Female	54	50.4	107	(80.4-139.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	50	57	87.7	(65.1-115.6)
Female	0	0.4	nc	(nc-nc)	Female	54	50.4	107	(80.4-139.7)
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	7.5	79.9	(29.2-173.9)	Male	50	57	87.7	(65.1-115.6)
Female	13	6.8	190.9	(101.5-326.5)	Female	54	50.4	107	(80.4-139.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brockton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	85	84.5	100.6	(80.4-124.4)	Male	30	57.4	52.2	(35.2-74.6)
Female	28	32.2	86.9	(57.7-125.5)	Female	24	50	48	(30.8-71.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	13	18.4	70.6	(37.5-120.7)	Male	13	15.5	83.7	(44.5-143.2)
Female	15	15.9	94.4	(52.8-155.7)	Female	13	13.1	99.4	(52.9-170)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	37	50.7	72.9	(51.3-100.5)
Female	307	357.8	85.8	(76.5-95.9)	Female	47	43.4	108.2	(79.5-143.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	24	13.8	174.4	(111.7-259.6)	Male	43	38.5	111.6	(80.8-150.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	126	97.8	128.9	(107.4-153.5)	Female	36	32.5	110.8	(77.6-153.5)
Female	108	102.6	105.3	(86.4-127.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	27	23.3	116	(76.4-168.7)	Male	324	327	99.1	(88.6-110.5)
Female	8	6.5	122.7	(52.8-241.7)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	4	8.3	nc	(nc-nc)	Male	7	14.2	49.5	(19.8-101.9)
Female	9	7.2	125.8	(57.4-238.7)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	53	47.5	111.5	(83.5-145.8)	Female	75	81.7	91.8	(72.2-115)
Female	25	28.4	88	(56.9-129.9)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	21	12.8	163.9	(101.4-250.5)	Male	33	34.9	94.6	(65.1-132.9)
Female	5	4.2	120	(38.7-280)	Female	23	27.2	84.7	(53.7-127.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	31	27.5	112.7	(76.5-159.9)	Male	189	155.2	121.8	(105-140.4)
Female	15	9.7	155.4	(86.9-256.4)	Female	198	167.4	118.3	(102.4-135.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brookfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	3.8	236.6	(108-449.2)	Male	3	2.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	17	14.5	117.4	(68.3-187.9)	Female	2	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	4.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	7	4	174	(69.7-358.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	13	15.3	85.1	(45.3-145.5)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.1	nc	(nc-nc)	Female	6	3.4	176.9	(64.6-385.1)
Female	0	1.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	9	7.1	126.1	(57.6-239.5)
Female	3	0.4	nc	(nc-nc)	Female	5	7	71	(22.9-165.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	54.8	87.6	(64.6-116.2)	Male	45	35.9	125.2	(91.3-167.5)
Female	17	21.5	79.2	(46.1-126.8)	Female	51	33.1	154	(114.6-202.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	18	10.8	166.7	(98.7-263.4)	Male	11	9.8	112.8	(56.2-201.8)
Female	12	10	120.3	(62.1-210.1)	Female	8	8.6	93.1	(40.1-183.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	37	31.7	116.8	(82.2-160.9)
Female	268	225.6	118.8	(105-133.9)	Female	32	28.5	112.4	(76.9-158.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	8.9	nc	(nc-nc)	Male	20	23.2	86.1	(52.5-132.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	45	61.7	72.9	(53.2-97.5)	Female	23	21	109.4	(69.3-164.2)
Female	59	68.7	85.9	(65.4-110.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	20	18	111.4	(68-172)
Male	7	14.5	48.2	(19.3-99.3)	Female	23	20.8	110.4	(70-165.6)
Female	3	4.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	205	200.7	102.2	(88.7-117.1)
Male	4	5.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	6	5.1	117.9	(43.1-256.7)	Male	9	13	69.3	(31.6-131.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	8	8.5	94.5	(40.7-186.2)
Male	33	28.8	114.7	(79-161.1)	<b><u>Testis</u></b>				
Female	24	18.1	132.4	(84.8-197)	Male	14	9.2	151.6	(82.8-254.4)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	7.9	nc	(nc-nc)	Male	25	13.3	187.7	(121.4-277)
Female	0	2.6	nc	(nc-nc)	Female	55	48.4	113.6	(85.6-147.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	37	21.6	171.5	(120.8-236.4)	Female	45	51.7	87.1	(63.5-116.5)
Female	27	17.5	153.9	(101.4-223.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	699	733.9	95.3	(88.3-102.6)
Male	6	16.8	35.8	(13.1-77.9)	Female	809	791.4	102.2	(95.3-109.5)
Female	6	6.3	95.6	(34.9-208.2)					
<b><u>Lung and Bronchus</u></b>									
Male	70	98.6	71	(55.4-89.7)					
Female	70	107.7	65	(50.6-82.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Buckland

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	12	9.2	130.8	(67.5-228.6)	Female	0	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	2.8	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.8	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	10	9.7	102.6	(49.1-188.7)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.3	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	29	33.8	85.8	(57.4-123.2)
Male	1	0.8	nc	(nc-nc)	Female	38	30.8	123.4	(87.3-169.4)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	1	4.5	nc	(nc-nc)					
Female	5	4.3	116.1	(37.4-270.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Burlington

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	27.7	122.8	(85-171.6)	Male	20	18.3	109.4	(66.8-168.9)
Female	7	9.7	71.9	(28.8-148.2)	Female	14	14.1	99.3	(54.3-166.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	5.4	186.3	(89.2-342.6)	Male	7	5.1	138.1	(55.3-284.6)
Female	1	4.4	nc	(nc-nc)	Female	5	4	125.7	(40.5-293.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	21	15.9	132.2	(81.8-202.1)
Female	115	106.2	108.3	(89.4-130)	Female	15	12.9	116.7	(65.3-192.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.8	nc	(nc-nc)	Male	9	12.2	74	(33.8-140.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	27	31.2	86.6	(57.1-126)	Female	8	9.6	83.5	(36-164.5)
Female	29	30	96.8	(64.8-139.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	4	7.7	nc	(nc-nc)	Male	101	108.8	92.8	(75.6-112.8)
Female	3	2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	15.2	131.8	(80.5-203.6)	Female	33	25	131.9	(90.8-185.3)
Female	7	8.5	81.9	(32.8-168.8)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	2	4.2	nc	(nc-nc)	Male	17	10.6	159.8	(93-255.9)
Female	1	1.3	nc	(nc-nc)	Female	8	7.6	105.3	(45.3-207.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	9	8.8	102.1	(46.6-193.8)	Male	52	51.7	100.6	(75.1-131.9)
Female	0	2.9	nc	(nc-nc)	Female	58	52.3	111	(84.3-143.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cambridge

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	74.5	52.3	(37.2-71.5)	Male	59	52.9	111.5	(84.9-143.8)
Female	21	28.6	73.3	(45.4-112.1)	Female	47	49.9	94.3	(69.3-125.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	18	17.4	103.7	(61.4-163.9)	Male	18	13.5	133.3	(79-210.7)
Female	14	15	93.5	(51.1-157)	Female	12	11.6	103.4	(53.4-180.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	45	46.8	96.2	(70.1-128.7)
Female	271	320.5	84.5	(74.8-95.2)	Female	28	39.7	70.5	(46.8-101.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	13.8	65.1	(29.7-123.6)	Male	27	33.6	80.3	(52.9-116.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	81	85.8	94.4	(74.9-117.3)	Female	22	29.9	73.5	(46.1-111.3)
Female	79	91.5	86.3	(68.3-107.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	10	20.2	49.6	(23.7-91.1)	Male	275	280.5	98	(86.8-110.3)
Female	4	5.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	9	10.9	82.8	(37.8-157.2)	Male	24	21.3	112.8	(72.2-167.8)
Female	7	9.1	77.2	(30.9-159.1)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	26	41.8	62.2	(40.6-91.2)	Female	73	73.6	99.2	(77.7-124.7)
Female	12	25.6	46.9	(24.2-82)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	8	11.1	72.3	(31.1-142.5)	Male	18	31.7	56.8	(33.6-89.8)
Female	2	3.8	nc	(nc-nc)	Female	21	24.8	84.8	(52.5-129.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	20	23.7	84.3	(51.5-130.2)	Male	106	135.6	78.2	(64-94.5)
Female	13	8.6	150.7	(80.2-257.7)	Female	110	149	73.8	(60.7-89)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Canton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	27	62.9	(36.6-100.7)	Male	17	16.9	100.8	(58.7-161.4)
Female	6	10.4	57.7	(21.1-125.5)	Female	9	13.7	65.7	(30-124.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.8	103.6	(33.4-241.7)	Male	5	4.8	105.1	(33.9-245.2)
Female	4	4.2	nc	(nc-nc)	Female	8	4.1	194.6	(83.8-383.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	14	14.9	93.7	(51.2-157.2)
Female	93	101.6	91.6	(73.9-112.2)	Female	16	13.1	122	(69.7-198.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.5	nc	(nc-nc)	Male	11	11	100.1	(49.9-179.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	36	30.1	119.5	(83.7-165.5)	Female	8	9.4	85.4	(36.8-168.3)
Female	30	33.1	90.7	(61.2-129.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	11	8.8	125	(62.3-223.7)
Male	8	7	113.9	(49-224.4)	Female	9	10.2	88.6	(40.4-168.2)
Female	1	2.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	92	95.9	95.9	(77.3-117.7)
Male	1	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.6	nc	(nc-nc)	Male	2	6.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	4.1	nc	(nc-nc)
Male	9	13.6	66.3	(30.2-125.8)	<b><u>Testis</u></b>				
Female	8	8.3	96.6	(41.6-190.4)	Male	1	2.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	3.8	nc	(nc-nc)	Male	6	5.8	104.1	(38-226.6)
Female	0	1.2	nc	(nc-nc)	Female	25	17.8	140.3	(90.8-207.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	16	10.2	156.3	(89.3-253.8)	Female	24	22.9	104.7	(67.1-155.8)
Female	5	8	62.9	(20.3-146.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	345	350.1	98.5	(88.4-109.5)
Male	7	8	87.2	(34.9-179.6)	Female	357	358.3	99.6	(89.6-110.5)
Female	0	3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	44	48.2	91.3	(66.3-122.6)					
Female	64	51.2	124.9	(96.2-159.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;